Patrick Ezeh

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

J. Tabernero, K. Kern, H. Soares, 2017, Targeted Oncology.

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

D. Chakrabarti, A. Shaw, E. Felip, 2018 .